Cibadrex

Quick links to important sections

Cibadrex

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cibadrex

Quick Facts

Property Description
Active Ingredients Benazepril hydrochloride, Hydrochlorothiazide
Form Tablet (Oral solid dosage form)
Pharmacological Class ACE Inhibitor / Thiazide Diuretic Combination
Common Use (General) Management of Hypertension (High Blood Pressure)
Origin Synthetic

Cibadrex is a prescription-only fixed-dose combination product designed for the long-term management of high blood pressure, or hypertension, in adult patients. This medication is clinically recognized for its reliable ability to lower and control blood pressure, serving as an efficient therapeutic option. It is classified as an antihypertensive agent because it combines two active components into a single oral tablet preparation.

What Type of Medicine is Cibadrex?

The dual nature of Cibadrex places it within two major pharmacological classes: it is an Angiotensin-Converting Enzyme (ACE) inhibitor and a thiazide diuretic. This combination approach provides a superior overall blood pressure-lowering effect compared to single-agent therapy in many patients. The specific formulation of Benazepril and Hydrochlorothiazide is frequently prescribed when monotherapy has proven insufficient to achieve target antihypertensive activity.

Composition and Origin: The Dual Active Ingredients

The medicine's formulation contains two distinct active ingredients of synthetic origin: Benazepril hydrochloride and Hydrochlorothiazide. The preparation is supplied as a tablet for oral administration. Benazepril acts as a prodrug, which the liver converts into the active metabolite, Benazeprilat, while Hydrochlorothiazide is an active diuretic compound. This specific pairing is one of the most studied and utilized fixed-dose combinations for managing chronic hypertension.

How the Combination Provides Antihypertensive Activity

The general purpose of the combination is to synergistically reduce the strain on the cardiovascular system. The ACE inhibitor component helps to relax and widen blood vessels by blocking the formation of a potent constricting substance. Concurrently, the thiazide diuretic component increases the kidney’s ability to excrete sodium and water, reducing the overall intravascular fluid volume through enhanced diuresis. This simultaneous mechanism of effect provides comprehensive action toward achieving and maintaining target blood pressure levels in a single dose.

Regulatory References

  1. Benazepril and Hydrochlorothiazide - MedlinePlus

What side effects are possible with Cibadrex?

Possible Side Effects and Safety Information

The safety profile for Cibadrex (Benazepril/Hydrochlorothiazide) is formally documented in government regulatory prescribing information, classifying potential adverse reactions by frequency and physiological system. This information is intended to communicate the medicine’s officially documented risk profile.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped based on how often they are reported in clinical use. Those classified as common in regulatory documents include headache, dizziness, fatigue, and a dry cough. These are the most frequently observed effects during treatment. Less common reactions reported in official labeling include palpitations, insomnia, nausea, and rash.

System-Organ Classes and Serious Reactions

The official label groups effects into systems such as Nervous System Disorders and Metabolism and Nutrition Disorders (e.g., potential electrolyte imbalances and hyperglycemia). A serious, though rare, safety concern associated with the Benazepril component is angioedema, which involves swelling of the face, lips, tongue, or throat. Additionally, the Hydrochlorothiazide component is associated with an increased risk of non-melanoma skin cancer with long-term exposure, as documented in post-marketing reports.

Safety Restrictions and Considerations

Cibadrex is contraindicated in certain situations as specified in regulatory documents. This includes patients with a history of angioedema related to any prior ACE inhibitor use, those with anuria (inability to pass urine), and women in the second and third trimesters of pregnancy due to the risk of fetal toxicity. Specific attention is noted for patients with severe renal or hepatic impairment, as the medicine's use is restricted or requires caution in these groups. Furthermore, orthostatic effects like dizziness are noted to be more likely to occur at the start of therapy.

Overdose and Emergency Response

Overdosage with Cibadrex, a fixed-dose combination of Benazepril and Hydrochlorothiazide, is officially documented as primarily causing severe hemodynamic and electrolyte disturbances. The most likely acute clinical sign of overdosage is profound hypotension, or extremely low blood pressure, which may present with symptoms such as dizziness, lethargy, or confusion. Tachycardia or, less frequently, bradycardia may also occur.

Overdose is further characterized by significant fluid and electrolyte depletion, including documented instances of hypokalemia (low potassium) and hyponatremia (low sodium) due to the diuretic component. These severe imbalances and hypotension can lead to life-threatening complications, including circulatory shock and acute renal failure. The official regulatory guidance notes that the hypotensive effects may be particularly pronounced in patients with pre-existing volume depletion.

Seeking Immediate Medical Attention

Regulatory authorities require that individuals who suspect or confirm an overdosage must seek immediate medical attention and contact emergency services. Treatment for overdose is mandated as symptomatic and supportive treatment. Since no specific antidote is known, management focuses on aggressive measures to stabilize the patient, including intravenous fluid administration and correction of electrolyte disturbances. Hospital monitoring is required for close observation of vital signs, serum electrolytes, and renal function until stability is achieved.

Therapeutic Uses of Cibadrex

Quick Facts

  • Primary Therapeutic Domain: Management of high blood pressure (hypertension).
  • Goal of Therapy: To help lower and control blood pressure levels.
  • Benefit: May assist in reducing the potential risk of serious cardiovascular events, such as heart attack and stroke.

Cibadrex is an available treatment option for the management of high blood pressure, a condition also known as hypertension. It is typically prescribed to patients when treatment with a single medication is not providing sufficient control of blood pressure.

This medication is intended to help reduce elevated blood pressure readings. By assisting in the maintenance of blood pressure within a target range, the therapy may help support overall cardiovascular health and may assist in reducing the potential for severe, long-term complications. These complications can involve damage to the heart, brain, and kidneys.

Controlling hypertension is a crucial step in a comprehensive strategy to reduce the risk of serious events like stroke and heart attack. Cibadrex is used as part of a therapeutic regimen that often includes lifestyle adjustments.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Cibadrex use is strictly defined by regulatory eligibility criteria, primarily for adult patients managing hypertension. Use in the pediatric population is not established, as safety and effectiveness have not been demonstrated.

Contraindications (Must Not Use)

Population/Condition Regulatory Status
Pregnancy (2nd & 3rd trimesters) Contraindicated (Must be discontinued upon detection)
Angioedema (History of) Contraindicated
Anuria (Inability to pass urine) Contraindicated
Sulfa Drug Allergy Contraindicated
Concomitant use with Aliskiren (in diabetic patients) Contraindicated
Concomitant use with a Neprilysin Inhibitor Contraindicated (e.g., sacubitril)

Restricted or Conditional Use

Use of Cibadrex requires special consideration in several populations:

  • Renal Impairment: The medicine is not recommended for patients with severe renal impairment defined as creatinine clearance le 30 mL/min.
  • Hepatic Impairment: Caution and monitoring are necessary for patients with liver disease.
  • Lactation: Both active ingredients are excreted in breast milk; a decision must be made to either discontinue breastfeeding or discontinue the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cibadrex (Benazepril/Hydrochlorothiazide) has documented interaction patterns based on its dual pharmacological classification, as stated in official regulatory labeling.

Formal Contraindications and Timing Rules

Co-administration with Neprilysin Inhibitors (e.g., Sacubitril/Valsartan) is strictly contraindicated due to the significantly increased risk of angioedema. A mandatory 36-hour separation period is required when switching to or from these medicines. Use with the Direct Renin Inhibitor Aliskiren is also formally contraindicated in patients with diabetes.

Pharmacodynamic and Exposure Interactions

The combination should not be co-administered with Potassium Supplements or Potassium-sparing Diuretics, as this carries an increased risk of hyperkalemia (elevated serum potassium). The concomitant use of Lithium is documented to increase serum levels and the potential for toxicity. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause deterioration of renal function and can reduce the blood pressure-lowering effect. This renal risk is officially noted as higher in elderly or volume-depleted patients.

Exposure-modifying interactions are also documented: the absorption of the Benazepril component may be decreased by co-administered Aluminum Hydroxide. The absorption of the active ingredients is officially not clinically influenced by food.

Mechanism of Action

Cibadrex is a fixed-dose combination product containing benazepril and hydrochlorothiazide.

Benazepril is a pro-drug that is hepatically cleaved to its active metabolite, benazeprilat. Benazeprilat functions as a competitive inhibitor of the angiotensin-converting enzyme (ACE), a peptidyl dipeptidase. ACE inhibition prevents the conversion of angiotensin I to the potent vasoconstrictor, angiotensin II. The resulting decrease in circulating angiotensin II reduces vasopressor activity and lowers the stimulation of aldosterone secretion by the adrenal cortex. This cascade decreases systemic peripheral vascular resistance and modulates renal sodium and fluid retention.

Hydrochlorothiazide is a thiazide diuretic that acts by directly inhibiting the sodium-chloride cotransporter (NCC) located on the apical membrane of the distal convoluted tubule in the kidney. This antagonism reduces the reabsorption of sodium and chloride ions from the tubular lumen. The increased delivery of sodium and water to the collecting duct promotes natriuresis and diuresis, leading to a reduction in plasma and extracellular fluid volume.

Dosage and Administration Information

Cibadrex is a fixed-dose combination medicine intended for oral administration as a tablet for the long-term management of high blood pressure. The tablets must be swallowed whole with water and should not be broken, crushed, or chewed, as this ensures the controlled release and proper delivery of the active ingredients. The medication is taken once daily and may be administered without regard to meals to maintain consistency in the regimen.

The official dosing regimens establish a structured approach to therapy. For adult patients, treatment typically initiates with a standard dose of 10 mg Benazepril / 12.5 mg Hydrochlorothiazide once per day. The dosage may be subsequently increased, based on the patient's blood pressure response, up to the maximum recommended daily dose of 20 mg Benazepril / 25 mg Hydrochlorothiazide. Dose adjustments are not made daily; the standard protocol requires a titration interval of approximately two to three weeks to accurately gauge the full effect of the current dosage before any increase is instituted.

This combination product is generally utilized in the therapeutic plan when initial monotherapy (single-drug treatment) has not been sufficient to achieve target blood pressure control. Concerning specific patient groups, the combination product's safety and efficacy have not been established in pediatric patients. Use in adults with severe renal impairment requires caution as defined by prescribing information. To ensure adherence to the prescribed frequency, if a routine dose is missed, the instruction is to skip the missed dose entirely and continue with the next scheduled dose at the regular time; taking a double dose is explicitly avoided.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cibadrex

Evidence for Use in Managing High Blood Pressure (Hypertension)

Research exploring this combination was studied for managing high blood pressure, a condition associated with outcomes related to systemic or functional imbalance. The core of the evidence base consists of Randomized Controlled Trials (RCTs). The research focused on measuring outcomes monitoring physiological strain or stress, specifically by recording systolic and diastolic blood pressure readings. Findings describe patterns observed in these studies, where measurements of blood pressure often showed a difference in outcomes monitored in the combination group compared to the groups receiving only one of the active components. However, the initial follow-up durations were limited, meaning certainty remains low regarding outcomes after many years of use based on these initial trials alone.


Comparing Cibadrex to Other Treatments in Clinical Trials

Research has also explored how this combination was evaluated against other types of fixed-dose combination treatments. Trials assessed how different treatments performed in helping participants achieve pre-set target blood pressure levels. Data show patterns related to target achievement. Trials described patterns related to target achievement with a measured difference between the combination and single-ingredient treatments. However, when the combination was evaluated against other types of fixed-dose combination treatments, findings were varied. Evidence quality varies across studies, and in some cases, comparative evidence is lacking, meaning the research provides limited insight into differences between this combination and some other options available for high blood pressure management.


Long-Term Studies and Follow-up for Cardiovascular Outcomes

Research has included large-scale trials designed to monitor patient groups over extended periods to observe rates of long-term clinical outcomes (such as specific cardiovascular events) in patients with high cardiovascular risk. The evidence derived from these settings contributes to understanding the long-term patterns of cardiovascular outcomes in the observed populations. Research describes the rates of these events and how they were associated with the specific conditions under which the studies were conducted. These long-term observations contribute to the broader evidence landscape by describing group patterns over years, rather than just the immediate changes.


Areas of Research Uncertainty and Study Limitations

Research contributes to understanding symptom patterns, but it also highlights what is still uncertain. One key area of uncertainty is the variability observed when comparing the combination to other treatments, as some head-to-head trial findings were mixed. Furthermore, follow-up durations were short, and there is limited information for long-term outcomes. Data for certain groups remain insufficient; for example, data for the pediatric population are still emerging and limited, meaning research provides limited information regarding individual response patterns in that age group.

Frequently Asked Questions (FAQ)

Common questions about Cibadrex (FAQ)

Q: What is the primary approved use for Cibadrex?

A: The approved professional use for the Cibadrex combination drug is the long-term management of high blood pressure (hypertension). Official product information states this as its primary indication. One of the active ingredients, benazepril (an ACE inhibitor), is documented in clinical use for managing related cardiovascular conditions like heart failure.


Q: Do most people take Cibadrex for a short time or long-term?

A: Official information indicates this medication is approved for the long-term management of hypertension. Consistent daily administration is required to maintain its effect over time. It is not intended as a short-term treatment.


Q: Is there a generic version of Cibadrex available?

A: Yes, the combination of active ingredients—benazepril hydrochloride and hydrochlorothiazide—is available as a generic product. Cibadrex is one brand name for this specific combination.


Q: How long does it usually take for Cibadrex to start working?

A: Regulatory documents indicate that the blood pressure-lowering effect is often measurable within an hour of taking a dose, with peak reduction achieved in two to four hours. However, the maximum reduction in blood pressure with any dose is generally achieved after one to two weeks of chronic therapy.


Q: What happens if I forget to take a tablet?

A: Official instructions state that if a dose is missed, the patient should skip the missed dose and continue with their regular schedule at the usual time. Taking two doses at once to compensate for a missed dose is explicitly advised against in the prescribing information. Official documents indicate that taking an extra dose may lead to increased side effects, such as low blood pressure or dizziness.


Q: If I feel better, can I just stop taking Cibadrex?

A: Stopping the medication requires supervision by a healthcare provider. Official warnings note that sudden discontinuation of ACE inhibitors like benazepril has been associated with a rapid increase in blood pressure in some studies. Any decision to stop the medication must be managed by a qualified professional.


Q: How is Cibadrex typically stopped when a patient no longer needs it?

A: The process for discontinuing the medication is managed by a healthcare provider. ACE inhibitors are often discontinued by gradually reducing the dose over a period of time. This controlled process is used to help prevent the risk of a rapid increase in blood pressure.


Q: Can Cibadrex be split or crushed?

A: No, official prescribing information directs that the tablets must be swallowed whole. The tablets should not be broken, crushed, or chewed. This measure is required to ensure the medication's proper delivery and effectiveness.


Q: Does alcohol interact with Cibadrex?

A: Yes, official documentation indicates that alcohol can interact with this medication. Alcohol consumption can increase the risk for orthostatic hypotension (a form of low blood pressure that occurs when standing up) and may cause dizziness or drowsiness. Official documentation notes that alcohol use should be avoided while taking thiazide diuretics.


Q: Are there any specific cold or flu medicines to avoid while on Cibadrex?

A: Official documentation advises caution regarding cold and flu medicines that contain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which may reduce the medicine’s blood pressure-lowering effect and affect kidney function. Official labeling states that potassium supplements or salt substitutes containing potassium must be avoided.


Q: Why are people often told to avoid potassium-rich salt substitutes while on certain blood pressure drugs, including Cibadrex?

A: This caution is due to the risk of hyperkalemia, which is an elevated level of potassium in the blood. The benazepril component of the medication reduces the body's ability to excrete potassium. Since most salt substitutes contain potassium instead of sodium, using them can cause potassium to build up.


Q: Is it common to feel tired after starting Cibadrex?

A: Yes, official regulatory documents classify fatigue (tiredness) as a common adverse reaction associated with the active ingredients in this combination product.


Q: Does Cibadrex cause weight gain or weight loss?

A: Official safety information for the combination product does not commonly list weight gain or weight loss as a reported side effect. However, a significant weight gain is listed in regulatory documents as a serious sign that may indicate fluid or electrolyte problems, which should be reported.


Q: Is Cibadrex safe for people with liver problems?

A: The use of this medication requires caution and close monitoring for patients with existing liver problems (hepatic impairment). Official warnings state that the medication can potentially cause liver problems, and minor fluid or electrolyte alterations may lead to serious changes in brain function.


Q: Does Cibadrex contain lactose or gluten?

A: Based on the official product labeling for the combination tablet, the inactive ingredients do include lactose monohydrate. Information regarding gluten is typically not specified in the main product label. Patients with a severe sensitivity should consult the full package insert or a pharmacist for their specific prescription.

How should Cibadrex be stored and disposed of?

How to Store and Dispose of Cibadrex?

Official regulatory guidelines dictate specific requirements for storing and discarding Cibadrex tablets to maintain their stability and ensure safety.

Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), and protect from freezing and excess heat.
Protection Keep the tablets in the original container and ensure the container is tightly closed. Store away from direct light and excess moisture.
Child Safety Keep out of the sight and reach of children and store in a safe location.

Disposal Instructions

Cibadrex must not be disposed of in household trash or through wastewater (flushing down the toilet), as specified by environmental protection guidelines. To discard unused or expired tablets, official guidance directs patients to consult a pharmacist or a recognized local medicine take-back program for appropriate disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cibadrex found in:

A-Z Index: